Shares of Incyte Corp. (NASDAQ:INCY) have been assigned a consensus rating of “Buy” from the twenty-three brokerages that are presently covering the company. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twenty-one have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $105.41.

INCY has been the topic of several recent research reports. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Incyte Corp. in a research note on Wednesday, September 28th. SunTrust Banks Inc. began coverage on shares of Incyte Corp. in a research report on Friday, August 5th. They set a “buy” rating and a $105.00 price target on the stock. Piper Jaffray Cos. reissued a “buy” rating and set a $102.00 price target (up previously from $76.00) on shares of Incyte Corp. in a research report on Monday, August 1st. Zacks Investment Research raised shares of Incyte Corp. from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a research report on Tuesday, July 19th. Finally, Leerink Swann reissued a “buy” rating on shares of Incyte Corp. in a research report on Monday, July 18th.

Incyte Corp. (NASDAQ:INCY) opened at 104.51 on Friday. Incyte Corp. has a 1-year low of $55.00 and a 1-year high of $118.49. The company has a 50-day moving average of $91.34 and a 200 day moving average of $83.62. The stock has a market cap of $19.69 billion, a P/E ratio of 140.47 and a beta of 0.79.

In other news, EVP Paula J. Swain sold 20,000 shares of the stock in a transaction that occurred on Friday, September 23rd. The stock was sold at an average price of $90.00, for a total value of $1,800,000.00. Following the completion of the sale, the executive vice president now directly owns 49,248 shares of the company’s stock, valued at $4,432,320. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Reid M. Huber sold 2,715 shares of the stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $109.95, for a total value of $298,514.25. The disclosure for this sale can be found here. 13.70% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the stock. Pictet Asset Management Ltd. increased its stake in Incyte Corp. by 241.5% in the second quarter. Pictet Asset Management Ltd. now owns 760,513 shares of the biopharmaceutical company’s stock valued at $64,195,000 after buying an additional 537,800 shares during the last quarter. Capital International Investors increased its stake in Incyte Corp. by 9.2% in the second quarter. Capital International Investors now owns 5,918,033 shares of the biopharmaceutical company’s stock valued at $473,324,000 after buying an additional 499,536 shares during the last quarter. Marshall Wace LLP increased its stake in Incyte Corp. by 224.0% in the second quarter. Marshall Wace LLP now owns 637,663 shares of the biopharmaceutical company’s stock valued at $51,000,000 after buying an additional 440,877 shares during the last quarter. Capital Fund Management S.A. purchased a new stake in Incyte Corp. during the second quarter valued at $33,288,000. Finally, Eaton Vance Management increased its stake in Incyte Corp. by 246.2% in the second quarter. Eaton Vance Management now owns 511,787 shares of the biopharmaceutical company’s stock valued at $40,933,000 after buying an additional 363,939 shares during the last quarter. 92.40% of the stock is owned by institutional investors and hedge funds.

About Incyte Corp.

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK).

5 Day Chart for NASDAQ:INCY

Receive News & Stock Ratings for Incyte Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corp. and related stocks with our FREE daily email newsletter.